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Endometrial carcinoma is the most common gynecological malignancy and greatly affects 
global disease burden. Despite it being among the most common cancers it is relatively  
understudied and until recently poorly understood. Diagnostics of endometrial carcinoma 
have been underdeveloped for many years resulting in perpetual poor interobserver 
reproducibility in turn inhibiting correct diagnosis and complicating comparisons of clinical 
trials. In this thesis we used a three-tiered approach in trying to improve endometrial 
carcinoma diagnostics: strictly improving morphological criteria, adding 
immunohistochemistry (IHC)/biomarker panels, as well as genomics data in order to 
improve diagnostic and prognostic ability.  
In study 1 we compared standard FIGO grading of endometrial carcinoma to a newly 
developed morphologic system we named cell-type independent (CTI). We compared 
interobserver reproducibility using both systems in 70 patient`s endometrial biopsies. We 
could not identify any significant improvement in the form of increased interobserver 
reproducibility nor increased accuracy when compared to final hysterectomy diagnosis. We 
conclude that the limitations of the biopsy setting hampered the CTI system`s ability to 
outperform current FIGO grading system and that the assessment of nuclear grade, no 
matter what the definitions of a high nuclear grade are, remain subjective. 
In study 2 12 separate subspecialized gynaecological pathologists reviewed pathology 
slides of 70 cases of endometrial biopsies. We compared the interobserver agreement when 
adding a biomarker panel (IHC for p53, ER and PGR and DNA ploidy analysis) to only 
standard morphology diagnosis with accompanying results of final hysterectomy diagnosis. 
The addition of a biomarker panel increased interobserver agreement from 75,8%, kappa = 
0.52 to 84%, kappa= 0.68. Diagnostic agreement to final hysterectomy diagnosis also 
increased with use of the panel, going from 83.6% to 88.7% agreement with final diagnosis 
after incorporating the panel in biopsy diagnosis (p<0.05). The two biomarkers p53 IHC 
and DNA ploidy analysis showed significant effect on up-or downgrading of tumors. We 
conclude that selective use of a simple biomarker panel greatly aids in endometrial biopsy 
diagnostics. 
Study 3 was a collaborative effort between Bern and Karolinska University Hospital we 
sought to implement a surrogate molecular marker in 604 patients with endometrial 
carcinoma in order to try to replicate the TCGA (The cancer genome atlas) molecular 
markers classifiers and to hopefully aid in endometrial carcinoma diagnostics and 
prognostics. The panel consisted of IHC for p53 (to define a p53mut group) and MSH2, 
MSH6, PMS2, MLH1 (to define a MMRd, mismatch repair defective, group) and Sanger 
sequencing of the POLE gene (to define a POLEmut) group. We found that this simple 
surrogate molecular marker, using readily available methods, could reproduce the findings 
of the TCGA and render four prognostically different molecular categories. We could 
however not prove an added prognostic benefit over current risk assessment prognostic 
tools, nor any benefit in adding a surrogate molecular marker to current prognostic markers. 
Moreover only one of the molecular groups (p53 mut) proved to be statistically significant 
marker for predicting Progression free survival (PFS) and overall survival (OS). From this 
we concluded that in the setting of non-selected group of patients consisting mostly of low 
grade tumors proving significant differences between each of the molecular groups couldn’t 
be done since progression events were so rare and the group as a whole behaved indolently. 
Nonetheless there are clear benefits with the addition of genomic data for other purposes 
such as aid in suitable patient selection for adjuvant treatment. 
In study 4 we conducted sequencing of exons 9-14 of the POLE gene in a cohort of 604 
patients with endometrial carcinoma in order to more deeply analyze mutation events and 
the phenotype of POLE mutated endometrial carcinomas. We found mostly previously 
described hotspot mutations but also a substantial number of mutations with unknown 
significance and characterized POLEmut tumors as occurring in mainly younger women 
with nulliparity and consisting predominantly of endometrioid endometrial carcinomas. 
This study shows that when POLE mutations are clearly defined as either hotspot mutations 
and/or POLE mutations with a known hypermutated phenotype this patient group of 
POLEmut had very good outcomes with only 1 recurrence in 38 patients. The Cox 
regression couldn’t however show any significant difference between POLEmut and non 
POLEmut tumors, however we believe again this was because we are dealing with a low 
risk EC population where both recurrence events and POLE mutations are rare, and thus we 
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Endometrial carcinoma (EC) in a lot of ways represents the female counterpart of prostate 
cancer. It is a common cancer although not widely known, it affects mostly older women, 
and the outcomes are generally good with relatively few cancers causing death from 
disease. Frequently, patients experience symptoms early in the cancer genesis and thus are 
discovered early, have no spread beyond primary site and are often cured with surgery 
alone.  Similar to prostate cancer the EC research area is largely underdeveloped in 
comparison to more research-intensive cancers such as breast or lung. This has in part, as 
will be described below, led to a poor understanding of EC tumor biology, ambiguous 
histopathological diagnostics and non-standardized and sometimes somewhat arbitrary 
treatment strategies. 
 
1.1 EPIDEMIOLOGY AND ETIOLOGY 
EC is the most common gynecological cancer, outnumbering all the other gynecological 
cancers combined. It is the sixth most common cancer in Swedish women with 1294 
reported cases in 20181. In 2018 roughly 382000 new cases were reported and 90000 deaths 
attributable to EC2,3 worldwide, making it the sixth most common cancer in women 
worldwide. Survival and mortality rates (5-year survival rates are roughly 80% for the 
whole patient group, and mortality rates 4/100000 women4) are relatively good, mostly due 
to EC causing early symptoms and thus being detected in early stages5. While the incidence 
rate in Sweden has been steady for the last decade it is believed the rates will rise in the 
future as the trend in most of the western world is a slow and steady increase in incidence 
rates6. Incidence is roughly 4-5 times higher in the western compared to the developing 
world. The increasing incidence and the geographical differences are attributed to lifestyle-
factors such as increasing obesity, diabetes mellitus and an aging population. As these 
trends in developed countries continue, EC mortality, morbidity and global disease burden 
are expected to rise3,7–9. 
EC, in general, is caused by either of two etiologically distinct pathways (type 1 and 2 
ECs), which differ in both histology and tumor genomics10(see below). The first is the 
hyper-estrogenic pathway accounting for roughly 80% of EC cases (“type 1 EC”). In 
summary any condition or medication (exo- or endogenous) which disrupts the balance of 
progesterone and estrogen resulting in increasing or unopposed levels of estrogen causes 
hyperplasia of the endometrium thus increasing risk of cancer development11,12. 
The most common risk factor for hypoestrogenism is obesity. Fatty tissue aromatizes 
androstenedione to estrogen causing hyperestrogenism, which in the setting of obesity is 
unopposed by progesterone13–15.  Infertility and nulliparity decreases levels of sex hormone 
binding globulin (SHBG) leading to increased levels of circulating estrogen16. Non-
combination (without combination of progestins) Estrogen replacement treatment (usually 
 
2 
for menopausal symptoms) leads to a 6-fold increased risk of EC development17, however 
only local estrogen treatment is not associated with an increased risk18.  Tamoxifen, an ER 
blocking agent used to treat women with ER+ breast cancers, paradoxically increases risk 
of EC by activating a large number of cell proliferation mechanisms in the uterine 
lining19,20.  Finally,  polycystic ovarian syndrome (PCOS), can cause prolonged anovulatory 
periods leading to  a persistent increase in circulating estrogen through a negative feedback-
loop thus increasing risk of endometrial proliferation21. Patients following this first pathway 
tend to have tumors of endometrioid low-grade histology, low-stage and generally have 
better outcomes. 
The second pathway (“Type 2 EC”) accounts for 10-20% of EC cases. These cancers are 
not clearly associated with elevated estrogen levels, although their direct causal events are 
poorly understood. Progression to type 2 EC, seems to arise from an atrophic i.e. non-
hyperestrogenic related background endometrium. There is a slight dichotomic age 
distribution in type 2 ECs, resulting in two age peaks, these patients tend to be older in 
comparison to type 1 ECs but at the same time type 2 ECs also occur in younger pre- and 
perimenopausal women to a much greater extent than type 1 ECs22–24.  In general, these 
women tend to be of normal weight, older and multiparous. The histology of theses tumors 
tends to be high grade and non-endometrioid. Even though type 2 ECs account for a small 
minority of EC cases they are more aggressive, causing roughly 50% of EC mortality25,26.  
Hereditary EC accounts for 1-5% of EC cases. Patients with Lynch syndrome have 
mutations in DNA mismatch repair proteins (MSH2, MSH6, MLH1, PMS2) causing 
microsatellite instability (MSI) and tumors with high mutational burdens. Patients with 
Lynch syndrome run a 40-60% lifetime risk of EC development and are usually younger 
than 50 years at cancer debut27,28. Patients who debut at young age and have a family 
history suggestive of Lynch syndrome should be screened for Lynch syndrome either using 
immunohistochemistry (IHC) or via oncogenetic counselling29–31. If patients are found to 
have Lynch syndrome they should be monitored via regular gynecological examination and 
vaginal ultrasound, and after child bearing years are over recommended prophylactic 
hysterectomy and bilateral salpingoophrectomy32. Cowden syndrome is another form of 
hereditary EC, although much more rare than Lynch syndrome. Patients with Cowden 
syndrome have a germ-line mutation of the tumor-suppressor gene PTEN and a 1-5% 
lifetime risk of developing EC33–35.   
Smoking, grand multiparity (birth of more than 5 children), and contraceptive progestin 
pills reduce the risks of developing EC17,36–38. This is accomplished by reducing effects of 
estrogen either by inducing higher metabolism (smoking), or by counteracting the effects of 





1.2 SYMPTOMS AND INITIAL CLINICAL ASSESSMENT 
 
The most common symptoms prompting clinical investigation for possible EC are 
postmenopausal bleeding, menorrhagia (excessive menstrual bleeding), pyometra and 
vaginal discharges39. Of note, a small number of ECs are incidental discoveries, either via 
imaging modalities done for other symptoms or after hysterectomies for other common 
causes (such as resections of leiomyoma).  
The first step in the clinical investigation involves gynecological examination including a 
transvaginal ultrasound (TVA). TVA helps identify patients where an endometrial biopsy is 
necessary; if the endometrium thickness is over 5 mm an endometrial biopsy is 
recommended to rule out EC as cause of bleeding39,40. However, if clinical suspicion of EC 
is high one should proceed to biopsy immediately to reduce the risk of delayed diagnosis 
and therefore treatment delay.   
Mandatory first steps when evaluating patients with EC include an examination of family 
and medical history that may suggest risk of a potential hereditary (Lynch syndrome) cause 
of cancer. Since many patients are older and comorbid a physical examination is needed to 
determine if any possible limitations of treatment exist, since not all patients will be able to 
endure the full extent of possible treatment even if it is deemed necessary. Once a diagnosis 
of EC has been made the next step is clinical and radiologic staging in order to help 
determine what treatment is best suited for the patient. The first steps include a TVA, pelvis 
sonography and/or Magnetic resonance imaging (MRI) to help determine myometrial depth 
invasion, tumor size, possible cervical invasion, lymph node metastasis, serosal 
involvement and/or possible local pelvic spread41,42. If histology shows a high risk/type 2 
EC (more on that below) a computed tomography (CT) of the chest and pelvis can be 
performed as to rule out possible metastases, however it rarely affects treatment choice 
since very few patients have metastasized disease at debut (2-3%)43.  
1.3 HISTOPATHOLOGY 
The WHO classification of EC has not changed much when comparing previous44 to 
current versions45, the histological classification has largely remained the same for a long 
time. It remains in line with the Bokhman10, two-tiered EC classification. The 
histopathology classification is based on tumor histotype and grade. This assessment 
categorizes patients into high and low risk groups, as tumor grade is highly associated with 
prognosis46. Therefore, the initial biopsy diagnosis of a tumor has a large impact on the 
patient, as it affects extent of surgery (lympadenectomy or no lymphadenectomy), possible 
neoadjuvant treatment and extent of initial clinical workup (see more on this below in risk 
assessment).  
The most important initial designation a pathologist makes is determining the tumor 
histotype, dividing tumors into endometrioid and non-endometrioid types. All non-
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endometrioid tumor types are by definition classified as high grade, whereas endometrioid 
tumors are further graded according to FIGO system (see below) of endometrioid tumors47.  
Endometrioid ECs represent the most common type, accounting for roughly 80% of EC 
cases25. These tumors originate in a background of hyper-estrogenic hyperplastic 
proliferative endometrium often with endometrioid intraepithelial neoplasia (EIN)/atypical 
complex hyperplasia48,49. The morphology of endometrioid ECs is reminiscent of normal 
proliferating endometrium. The prototypical growth pattern is of complex and jagged 
anastomosing glands forming glandular back-to-back patterns with cribriform structures. 
The epithelial lining consists of atypical large cylindrical cells with central large nuclei and 
an eosinophilic cytoplasm. These tumors often show greatly heterogenous morphology, 
including large areas of squamous, mucinous, solid, villoglandular and secretory 
differentiation50. Because of these heterogenous features they can be challenging to 
diagnose, especially with limited biopsy material. For endometrioid ECs the second step is 
to assess the histological grade, this determines if the tumor is low- or high grade (only 
endometrioid tumors undergo this second-step of grading as non-endometrioid histotypes 
are immediately graded as high-grade). This is done using the FIGO/WHO grading 
system45,47,51: 
1. Grade 1 tumors have <5% solid tumor growth. 
2. Grade 2 tumors have between 5-50% solid tumor growth. 
3. Grade 3 tumors have >50% solid tumor growth.  
Note that when assessing the extent of solid growth one must disregard solid areas with 
squamous differentiation, which can be difficult to distinguish from solid growth glandular 
components52,53. In addition to assessing and grading the architecture/extent of solid growth 
of a tumor, the degree of nuclear atypia is also assessed. If a tumor shows high grade 
nuclear atypia, deemed inappropriately high for its architecture, the tumor grade is 
upgraded by one grade54–57. In other words, a tumor with 30% solid growth (grade 2 
architecturally) but with high grade nuclear atypia is upgraded to a grade 3 tumor. Grade 1-
2 tumors endometrioid ECs are deemed low grade/low risk while grade 3 are high grade 
tumors with a substantially increased risk of metastasis and recurrent disease58–60. 
Of the non-endometrioid i.e. high grade tumors serous carcinomas are the most common 
representing roughly 1-5% of all ECs25. They generally affect older women in a 
background of atrophic endometrium. This is the most aggressive type of EC often 
presenting with peritoneal and lymphatic spread, with deep myometrial invasion and with 
high risk of local and distant recurrance26,61,62. They are morphologically characterized by 
papillary and micropapillary fronds and outgrowths that are lined by tightly packed highly 
atypical tumor nuclei. Tumor necrosis and a high mitotic rate are common. The lumens of 
the glands and papillary structures show an uneven undulating surface, which can be a 




Less common but nonetheless regularly encountered variant of non-endometrioid 
carcinoma is clear cell carcinoma, representing about 2% of all EC cases25. It is important 
to be aware of this entity as it behaves aggressively clinically, often show distant metastasis 
and has a high risk of extensive distant spread26,63–65.  Morphologically these tumors grow 
in a solid, tubulocystic or villous pattern and are lined by the defining feature of large 
polygonal cells with clear or bright slightly eosinophilic cytoplasm. These lining cells 
usually form a single layer on the underlying stroma sometimes forming another classical 
clear cell carcinoma feature of “hobnailing”, where the apical part of tumor cells protrude 
into the lumen imparting a hobnail appearance. The nucleic atypia varies from mild to focal 
severe and sometimes bizarre looking atypia. These cytologic features are important to 
notice as clear cell carcinoma architecturally can grow in a very similar pattern to serous 
carcinomas showing prominent papillary features66,67.  
The remaining high-grade EC variants are exceedingly rare but are worth mentioning as 
they behave highly aggressively clinically and are responsible for a substantial portion of 
cancer related deaths in EC. Firstly carcinosarcoma (previously called malignant mixed 
Mullerian tumor, MMT) is composed of both malignant epithelial and mesenchymal 
elements, essentially leading to mixed carcinoma and sarcoma appearance in the 
microscope.  Both elements are high grade. Recent molecular and IHC studies have shown 
that carcinosarcomas aren’t genuine mixed tumors but rather a sarcomatoid 
dedifferentiation of the epithelial component and the driver of the malignancy lies within 
the epithelial component23,68,69, therefore carcinosarcoma is best regarded as a metaplastic 
carcinoma. Secondly, a recent addition, is the variant of EC called dedifferentiated or 
undifferentiated EC (same entity but the name changes depending on if there remains a 
low grade remnant from which the de-/undifferentiated component arose from). These 
tumors are important as they can be difficult to differentiate from a grade 3 endometrioid 
EC but behave even more aggressively. Morphologically these tumors grow in a solid 
patternless non glandular pattern and are composed of small tumor cells with prominent 
dyscohesion70–72.   
Finally, ECs don’t just display growth pattern plasticity within each tumor category 
described above, they also show mixed histotype components. As many as 5% of ECs show 
features of mixed carcinoma73. Mixed carcinomas are composed of two or more distinctly 
clear histotypes, each one representing at least 5% of the tumor. The most common mixed 
carcinomas are mixed serous and endometrioid followed by mixed clear cell and 
endometrioid. These tumors are important to diagnose correctly as it seems they clinically 
behave as their worst component, that is a mixed carcinoma with a small serous component 







Figure 1. Examples of EC histology. Top two pictures are of endometrioid carcinomas, the 
top being a low-grade endometrioid cancer FIGO grade 1 with many gland formations and 
second from top high-grade (FIGO 3) solid growth with no gland formations. 
The bottom two are of a clear cell carcinoma, solid growth with many clear highly atypical 
cells (3rd from top) and bottom is a serous carcinoma with papillary and solid growth and 
high grade nuclear atypia with many mitoses. 
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1.4 IMMUNOHISTOCHEMISTRY OF EC 
As described above ECs display a wide variety of cytologic features and growth patterns 
which makes them diagnostically challenging increasing the risk of misdiagnosis77. 
Because of these challenges throughout the years a large number of studies have been 
focused on immunohistochemistry (IHC) in order to help combat these diagnostic issues. 
While IHC has been and is a cornerstone of EC diagnostics, the following summating 
statements in regards to the use IHC in EC diagnostics remain true;  
1. There is no magic single IHC marker which will make challenging cases easy to 
diagnose, therefore the use of IHC panels is advised78,79. 
2. Identifying cases where IHC is necessary can be difficult and determining whether 
IHC is needed for all cases (“reflex testing”) is equally difficult. 
3. Interpertation of results dicrepant from both histomorphologic assessment and 
discrepant from each other in a panel (that is different IHC markers pointing towards 
different diagnoses in a multiple marker IHC panel) in no easy task.  
That said, nowadays it is hard to imagine diagnosing ECs without the use of IHC as they 
greatly aid diagnosis. Probably the most broadly and frequently used IHC panel consists of 
p53, Estrogen receptor (ER) and progesterone receptor (PR). This panel is most often used 
when it is morphologically difficult to distinguish between a low grade endometrioid tumor 
and a high grade serous carcinoma. This is because most low grade endometrioid ECs are 
ER+ and PR+ while p53 is seen with a wildtype staining pattern and conversely serous 
carcinomas are ER-, PR- while p53 stains with a mutation pattern (either strong and 
complete or complete lack of expression, so called “null” mutational staining pattern)80. In 
fact this simple three stain panel is quite useful in distinguishing high- from low grade 
tumors as most high grade (serous, clear cell, undifferentiated) tumors are ER negative81,82. 
In the differential between serous and enometrioid carcinomas it is important to remember 
that roughly 30% of high-grade endometrioid ECs also show a p53 mutated staining 
pattern83. In the same differential another useful stain is p16, as most serous carcinomas a 
strongly positive while endometrioid carcinomas only show focal positivity84,85. Yet 









Figure 2. Examples of IHC outcomes. Top left is low-grade endometrioid EC with positive 
ER. Top right is an example of p53 wildtype-staining pattern with a heterogenous weak 
positive expression. Bottom pictures are examples of a p53 mutated-staining patterns, on 
the left a strong homogenous overexpression in all tumor cells and on the right a complete 
non-expression, so called null-pattern of mutation.  
De-/undifferentiated ECs can be diagnostically challenging. These tumors often lose 
expression of common gynecologic markers ER and PAX8, so identifying them as 
endometrial primaries can be difficult and a risk of misdiagnosing these tumors as poorly 
differentiated metastases exists. The difficulties are further compounded when 
morphologically trying to separate these tumors from solid growing high grade 
endometrioid and serous ECs.  Therefore it was a welcome sight when recent studies 
showed a large portion of these tumors show aberrant expression/loss of INI1 
(SMARCB1), BRG1 (SMARCA4) and BAF250a (ARID1A) 71,86,87, making them useful 
markers for identifying dedifferentiated ECs. Of note, a small portion of these tumors also 
showed a p53 mutated staining pattern, perhaps suggesting a different pathogenic (serous 
carcinoma-like) pathway86,88,89. 
In a small subset of tumors, clinical and radiological checkup cannot reliably differentiate 
between a primary EC or a primary cervical carcinoma. This is an important distinction 
because the two cancer types behave and are treated differently. If such a differential arises 
and morphological distinction alone is too difficult to tell them apart, an IHC panel 
consisting of CEA, p16, Vimentin, ER can be helpful90 as Vimentin is much more 
frequently expressed in ECs and p16 in cervical cancers. One must keep in mind that p16 
expression is often seen in high-grade ECs (clear cell, serous carcinoma)91,92. If a 
distinction between the two primaries still remains, an HPV analysis is recommended as 
cervical cancers are HPV driven/positive. Endometrial biopsies are also sometimes 
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undertaken in patients with apparent disease in both the ovaries and endometrium at which 
point a question of primary site arises. If the tumor is serous, which is almost always the 
case, a WT-1 stain can be useful as it is far more often expressed in ovarian primaries 
compared to its endometrial counterparts93,94.  
NapsinA and HNF1B have been identified as useful tools in diagnosing clear cell 
carcinomas of the ovary95–97. However, when applying these markers in the setting of EC 
their usefulness in identifying clear cell carcinoma diminishes. This is due to lack of 
specificity. While the markers are widely and strongly expressed in endometrial clear cell 
carcinoma, they are also expressed in a large numbers of serous and endometrioid ECs as 
well as some benign EC mimics98. 
A large number of other IHC markers have extensively been studied in the setting of ECs. 
For instance Her-2, Claudins, IMP2 and IMP3 have shown mixed sensitivity and specificity 
and are of limited clinical use78,99. Loss of expression for tumor suppressor PTEN has been 
shown in endometrioid ECs as well as small subset of undifferentiated and mixed 
carcinomas100, but despite efforts to optimize PTEN immunostaining protocols101 there still 
remains difficulty in interpreting the PTEN staining results as well as inter-laboratory 
differences in staining intensity79, making it a challenging immunomarker to use in 
everyday clinical practice. 
 
Tumor type IHC 
Endometrioid ER+, PR+, p53wt, p16 weak and patchy 
Clear cell  ER-, p53wt, p16 weak and patchy 
Serous ER-, p53mut, p16 strong 
Un-/dedifferentiated BRG1 and INI1 loss, p53wt, p16 weak 
Figure 3. Examples of EC types and their prototypical immunohistochemical phenotype. 
Carcinosarcoma left out because it is almost exclusively a morphological diagnosis. 
 
1.5 STAGING AND RISK STRATIFICATION 
Before 1988, ECs were staged clinically46,102, but in the late 1980s a series of clinical trials 
showed discrepancies between clinical stage and risk of extrauterine spread of disease, 
mostly affecting clinically low grade tumors (about 1/5th of the cases) 102,103. Since then 
ECs are staged surgically where a large emphasis of staging has been placed on surgical 
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pathology to asses myometrial depth invasion (more or less than 50%), presence of 
lymphovascular invasion (LVSI), involvement of the adnexa (fallopian tube and/or ovaries) 
and assess for possible invasion of the cervical stroma. The extensive surgical staging 
includes hysterectomy with bilateral oophorectomy as well as complete pelvic and 
paraaortal lymphadenectomy. Initially, peritoneal lavage for cytology was also 
recommended but has since been removed and is no longer considered mandatory for 
proper surgical staging104. However studies have shown that the outcome of peritoneal 
cytology is an independent prognostic factor105,106, which is why the latest 
recommendations suggest considering performing peritoneal lavage in cases with high-
grade (especially serous) ECs107. The benefits of a comprehensive surgical staging are 
accurate diagnosis and staging which in turn aids in tailor-making treatment and selection 
of patients in need of more aggressive adjuvant therapy. In 2009, the FIGO staging108 
classes were slightly modified, but largely remained the same since the late 1980s. They are 
summarized in Figure 4. 
Stage I Tumor confined to the uterus. 
Ia: Invasion <50% of myometrium. 
Ib: Invasion >50% of myometrium. 
Stage II Tumors involves cervical stroma. Must 
invade cervical stroma, tumors confined to 
endocervical epithelium are not to be 
regarded as stage II. 
Stage III Tumor outside the uterus confined to the 
pelvis or retroperitoneum. 
IIIA: cancer that invades to the serosa or 
the adnexa. 
IIIB: Cancer involves the vagina, 
parametrium or the pelvic peritoneum.  
IIIC: retroperitoneal node involvement. 
IIIC1: pelvic node involvement.  
IIIC2: paraaortic involvement. 
Stage IV Tumor outside the uterus. 
IVA: invasion to surrounding organs, i.e., 
invasion of the bowel or bladder.  
IVB: distant metastasis. 
Figure 4. The 2009 FIGO staging of endometrial carcinoma. 
 
 11 
In 2016 the ESMO-ESGO-ESTRO107,109 Consensus Conference led to the formation of a 
risk group assessment strategy based on the current FIGO staging. The conference 
recommended a slight revision of surgical staging of ECs with the addition of LVSI 
assessment and placed a stronger emphasis on histotype determination thus making correct 
diagnosis even more important. This led to the formation of six risk groups which would 
aid possible postoperative treatment decisions: 
• Low risk group: Stage I endometrioid, grade 1–2, <50%myometrial invasion, LVSI 
negative. 
• Intermediate: Stage I endometrioid, grade 1–2, ≥50%myometrial invasion, LVSI 
negative. 
• High-intermediate:  
-Stage I endometrioid, grade 3, <50%myometrial invasion, regardless of LVSI status.  
-Stage I endometrioid, grade 1–2, LVSI unequivocally positive, regardless of depth of 
invasion. 
• High: Stage I endometrioid, grade 3, ≥50% myometrial invasion, regardless of LVSI 
status. 
-Stage II 
-Stage III endometrioid, no residual disease 
-Non-endometrioid (serous or clear-cell, undifferentiated carcinoma, or 
carcinosarcoma) 
• Advanced: Stage III residual disease and stage IVa. 
• Metastatic: Stage IVb. 
These risk groups, together with a clinical physical assessment of ability to withstand 
further treatment, lay the base for decisions on postoperative treatment.  
Lastly, in this segment on staging, a brief but important note on lymphadenectomy (LA) in 
ECs. There are no clear definitions on what an adequate LA is and what the extent should 
be (below or above the inferior mesenteric artery). There are a few studies suggesting a 
survival benefit for patients whose LAs include at least 10-12 lymph nodes110–112, and 
studies suggesting that higher lymph node counts are associated with survival benefits111, 
making a pathology based lymph node count a possible surrogate marker of the adequacy 
of the LA. Furthermore, evidence of patient benefit of LA is uncertain and evidence 
supporting such practice thin. Large retrospective113 and single-center  studies111 show 
overall survival (OS) benefits but large randomized clinical trials114,115 (RCTs) showed 
neither OS nor disease specific survival benefits. Therefore, LA should be more considered 





Treatment decisions are based on the above described risk group assessment107 which 
incorporates both tumor stage and grade. While general principles of treatment are 
generally the same around the world, there is a large variability of treatment selection in 
any given national guideline. There certainly is a broad international agreement that low 
grade and stage tumors should be treated conservatively and high grade and stage tumors 
aggressively. The main uncertainties lie in the intermediate risk groups and with the 
decision of when a patient is suitable for administration of adjuvant treatment, be it RT or 
chemotherapy. Nonetheless the general guidelines of treatment for EC are described below.  
The mainstay of treatment for all patients with EC is hysterectomy with bilateral 
oophorectomy. For patients in the low and intermediate ESMO risk groups, LA is not 
necessary since risk of metastasis is very low116. For patients in high risk groups and above, 
LA for staging is recommended as risk of metastasis is significantly increased (by roughly 
5 times)117.  
For the vast majority of EC patients, the above treatments are sufficient for proper staging 
and even cure with very low risks of recurrence and distant metastases. For patients with 
stage 3-4 disease (advanced primary and metastatic disease according to ESMO 
categorization) the focus shifts to radical cytoreductive surgery and if not possible (either 
because the treatment would be too impairing because of anatomic location or because 
patients aren’t fit enough to endure extensive surgery), multimodal cytoreductive treatment; 
a combination of surgery and radiotherapy (RT). This has been shown to improve OS and 
progression free survival (PFS), especially if the cytoreduction is to no gross residual 
disease118. PFS and OS improved from 2,2 to 40,3 and 2,2 to 42,2 months (p<0.001) 
respectively, for patients with cytoreduction to no gross residual disease compared to 
patients who received no cytoreductive treatment. For advanced disease (bulky stage 3 and 
4) cytoreductive surgery should only be considered when there is a chance of no gross 
residual disease, as surgery for these patients with no hope of clearing all tumor burden 
does not improve survival rates119. 
Adjuvant radiotherapy, either in the form of vaginal brachytherapy or external beam 
radiation therapy (EBRT), should be considered for patients in the intermediate and 
intermediate-high risk groups. While the risk of recurrence is generally low, they benefit 
from preemptive irradiation to reduce risk of recurrence at the most common local 
recurrence site120,121. Adjuvant radiotherapy is however another hotly contested topic in the 
EC treatment field, because even though the local risk of recurrence is reduced, adjuvant 
RT has no impact on OS120,122, and isolated local vaginal recurrence is curable with isolated 
RT as sole treatment with success rates up to 100%123,124. This is why the current 
recommendations are only to consider such treatment options and not outright strongly 
recommend it for all patients.  
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Local recurrences in the pelvic region, vagina, paraaortal or pelvic lymph nodes, as well as 
isolated metastatic nodules in the liver or lung, are treated with combination of surgery and 
RT with relatively good outcomes of 40 % 5-year survival rates125,126.  
Finally, adjuvant chemotherapy (usually paclitaxel and carboplatin combinations) should be 
considered in stage 1 tumors with non-endometrioid histology as well as in stage 2 tumors 
with endometrioid histology with adverse factors (deep myometrial invasion, LVSI) as 
adjuvant chemotherapy reduces risk of local recurrence and metastases127,128. In FIGO stage 
3 and 4, advanced cancers chemotherapy is recommended as it improves both OS and 
PFR129,130. 
1.7 PROGNOSIS 
Tumor stage is the biggest determinant of outcome and since roughly 75-80% of patients 
are diagnosed with stage 1 disease the general prognosis for EC is quite good131. However, 
patients with late stage and high-grade tumors have poor outcomes and since most of them 
present late in life with short expected life expectancies most of them proceed to palliative 
treatment and best supportive care. The cumulative 5-year survival rates are roughly 80% 
for all EC patients.  Stage associated 5-year survival rates are roughly 95%, 80%, 55% and 






2 CURRENT ISSUES IN EC DIAGNOSTICS 
While some of the issues described below are problematic for us pathologists in everyday 
practice, it is important to take note of the bigger picture. Incorrect diagnostics lead to a 
host of problems that are far bigger than any individual diagnosis. While a single 
misdiagnosis may lead to incorrect under- or overtreatment in that case, a bigger issue lies 
in problems of standardization of treatment and comparing of clinical trials. It may be that 
the different results we see in clinical trials are a results of diagnostic discrepancies, making 
it difficult to contrast and compare outcomes of any given treatment, thus leading to the 
discrepancies in the way we treat EC patients and sometimes seemingly arbitrary treatment 
choices that do not affect OS. 
2.1 POOR REPRODUCIBILITY 
The many overlapping morphologic growth patterns for ECs cause a diagnostic struggle 
leading to poor inter- and intraobserver reproducibility and thus hardly trustworthy 
diagnostics. First of all, there is the problem of histotype assessment. In 2013, Gilks et al 
published a report comparing diagnoses of 3 experienced gynaeceological pathologists in 
56 cases of high-grade ECs (serous, clear cell, grade 3 endometrioid and carcinosarcoma). 
Even with the aid IHC markers, only a 62.5% (35/52) overall agreement with interobserver 
kappa values ranging from 0.57 to 0.68 (fair to moderate agreement)133 were achieved. 
Further studies have substantiated these results showing, at most, moderate agreement in 
evaluating histotype of ECs52,53 even when evaluating cohorts of mostly endometrioid ECs.  
Second of all, the assessment of percentage non-squamous solid area growth seems at times 
somewhat arbitrary and difficult but is a key factor in deciding tumor grade134,135. Thirdly 
the diagnostic criteria of nuclear atypia and what constitutes a severe high-grade nuclear 
atypia were ill-defined at the introduction of the FIGO classification, and assessment of 
nuclear atypia is and will remain highly subjective51,55.  
To combat these issues attempts were made to simplify the morphologic grading while 
retaining the grading systems prognostic power (see study number 1 below). Attempts at 
simplifying the grading by going over to a binary grading system and by assessing more 
robust features such as tumor necrosis, infiltrative growth pattern and removing the 5% 
solid growth limit showed slight reproducibility improvements over FIGO (interobserver 
kappa values 0.55 for FIGO and 0.65 for binary grading)136. Binary grading endeavors 
using architectural pattern, nuclear grade, and mitotic index also showed slight or no 
substantial improvement over current FIGO system59,134,137.  
Despite these efforts there still remains issues in the histopathological evaluation of tumors 
with only up to fair interobserver agreement. There is little support suggesting that this is 
because of poorly defined criteria but rather that the chosen criteria for diagnosing EC are 
and will remain subjective. This suggests the need to aid morphological diagnostics with 
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more robust objective tools and perhaps that the purely morphological diagnostic paradigm 
may have run its course. 
2.2 DIAGNOSIS OF ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA 
The diagnosis endometrial intraepithelial neoplasia (EIN) is important as it is a precursor to 
development of EC and the diagnosis can explain uterine bleeding symptoms and guide 
treatment138. There are two main issues with EIN, one is reproducibility of diagnosis and 
the other is sampling error. There have traditionally been two ways to diagnose these 
alterations. The WHO94 classification which divided lesions into: 
1) simple hyperplasia. 
2) complex hyperplasia 
3) simple hyperplasia with atypia  
4) complex hyperplasia with atypia.  
These categories were purely histomorphologically descriptive and clinicians found it 
difficult deciding course of action based on these diagnoses. There is also ample evidence 
that this categorization suffered from poor reproducibility between each category with 
frequent over- and underestimation disagreements135,139. However a new classification140,141 
system based their criteria on evaluation of gland to stromal area, cytologic change in focus 
of altered gland architecture, lesional size of more than 1 mm, and exclusion of cancer and 
mimics introduced three new categories: 
1) benign (benign endometrial hyperplasia) 
2) premalignant (endometrial intraepithelial neoplasia)  
3) malignant (EC) 
This simplified system seems to both increase the pathology reproducibility and simplify 
clinical decision making for the treating physician while retaining its prognostic 
power142,143. This is why this classification is now the preferred nomenclature for 
diagnosing premalignant conditions.   
The issue with both of these classifications, however, is sampling. Be it by dilation and 
curettage (D&C) or endometrial suction curette sampling, a large number of concomittant 
cancers (roughly 40%) are missed when comparing biopsy to final hysterectomy diagnoses 
in patients with a biopsy diagnosis of EIN or benign hyperplasia144,145. Studies suggest that 
the concomitant use of hysteroscopy during D&C limits the risk of missing coexistent 
cancers146,147. In either case the sampling issue is hard to overcome since technical 
restraints limit the sampling ability and extent of sampling of the uterine lining. This 
problem can be mitigated if knowledge that the biopsy finding of EIN or hyperplasia often 
is associated with EC. Thus patients with an EIN biopsy diagnosis should not simply be 
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dismissed, but lengthy follow-up and re-biopsies, if not outright hysterectomy, is 
warranted148. 
2.3 LYMPH NODE MACROSCOPIC EVALUATION AND EMBEDDING 
STRATEGY 
In above paragraphs the surgical issues in regard to incomplete definitions of the extent of 
LA have been described. While these issues are familiar we also know that lymph node 
counts can have an effect on both OS and PFR for patients with EC110,111,149. However, it is 
largely unknown what factors affect the number of lymph nodes attained in LAs. Is it just a 
question of surgical method and technique or does pathological processing have something 
to do with it? In a study by Euscher et150 al tissue was embedded from both pelvic and 
paraaortic LAs in a standard routine way by macroscopically identifying and fractioning 
lymph nodes, after which the remaining tissue was resubmitted as part of the study to 
identify to what extent pathologic processing affected lymph node counts. Eusher et al 
found that the number of lymph nodes did increase but no significantly so (64% of cases 
had additional lymph nodes after resubmission of tissue), and they found no other 
additional metastasis after resubmitting more tissue. They did also find significantly more 
lymph nodes in patients who underwent open surgery instead of laparoscopic or robot-
assisted surgery, suggestive the importance of surgical technique.  
However, in a more recent retrospective cohort study by Cormier et al151, they found that 
the most significant factor in correct staging and lymph node counts was which pathologist 
was doing the macroscopic evaluation. There clearly is a need for more research in order to 
precisely define both the surgical extent of LAs , and clear cut macroscopic pathologic 
procedures and embedding strategies (whole tissue embedding?) in order not to miss any 
lymph nodes or metastases.  
2.4 DISCREPANCY BETWEEN BIOPSY AND HYSTERECTOMY DIAGNOSIS 
Since biopsy diagnosis plays such an integral part in surgery planning (pre-operative risk 
assessment) it is disappointing to note that the diagnosis on biopsy specimen can differ 
from final hysterectomy diagnosis. This discrepancy may cause the need for additional 
second look surgery and/or unsuspected adjuvant treatment and is further exacerbated when 
considering the importance of a correct (low-grade) diagnosis in young women where 
uterine preserving surgery is a possibility. 
There is a large number of studies showing that a significant proportion of patients are 
upgraded to a higher FIGO grade when comparing biopsy to final hysterectomy 
diagnosis114,115,152–154. The studies show similar results in that between 25-35% of patients 
are upgraded. Fortunately, the vast majority of these upgrading events are patients being 
upgraded from FIGO grade 1 to 2. Only 2-5% will be upgraded to high-risk tumors (from 




Again, this is a difficult problem to resolve because most of these discrepancies can be 
explained by sampling issues. As ECs are heterogenous when the entirety of the tumor can 
be reviewed it is no surprise that diagnosis can change from a small sample of the tumor. 
Surely a small subset of these discrepancies can be explained by frank misdiagnosis, 
especially in cases of villoglandular growth in serous carcinomas, but this problem should 
be mitigated by the use IHC panels157,158. Another important aspect to consider is the 
prevalence of tumor heterogeneity both in growth patterns and mixed histotype tumors 
which is quite frequent in ECs159. It is important that treating physicians are aware of this 
grade-shift problem and plan for the possible need of more extensive treatment in cases 
where patients are upgraded to high-risk. 
2.5 P53 IHC INTERPRETATION 
Interpretation of p53 IHC can be quite challenging. Since the outcome of such a stain is 
critical, (positive mutation staining pattern is highly indicative of a high grade, mostly 
serous, tumor) it is important to be right. While the staining when interpreted correctly is 
highly congruent with actual TP53 mutational status160,161, the staining patterns can be 
difficult to read as 1) it is frequently expressed in normal tissue and 2) can be 
upregulated/slightly overexpressed due to a number of benign/ reactive causes. In 
interpreting the status of p53 it is important to follow the rule “all or nothing”. 
Nonsynonymous missense mutations cause a formidable overexpression in tumor tissue 
accounting for at least 80% of tumor cells to strongly express p53, or a complete zero-
expression (so called null-pattern caused by frame-shift, splice-site or a nonsense mutation) 
which both should be understood as mutation pattern staining162,163. 
2.6 MYOMETRIAL DEPTH INVASION 
Evaluation of myometrial depth invasion is an important prognostic step as it affects tumor 
stage47. However, the thickness of the myometrium varies in different anatomical regions of 
the uterus which is important to consider when evaluating depth of invasion. Since the stage 
difference is categorized by invasion of more or less than 50% of the myometrial thickness, 
the macroscopic evaluation (taking in account where anatomically the piece of tumor is 
sampled) of myometrial thickness is an important step in surgical pathology evaluation. 
A number of studies have reviewed various ways to measure myometrial depth invasion, 
their prognostic impact and reproducibility. Absolute depth of invasion (DOI, measured in 
mm from the endometrial myometrium interface to the deepest invasion point) and tumor 
free distance (TFD, measured in mm from the deepest point of invasion to the uterine 
serosal surface) are two examples of alternative ways of measuring myometrial invasion. In 
summary, most of these studies have actually shown that both DOI and TFD can be better 
predictors of recurrent disease, nodal involvement and disease mortality164–167, in 
comparison to traditional myometrial depth of invasion staging practices. However, when 
studying reproducibility both these variables have been shown to be slightly less 
reproducible when comparing to traditional myometrial invasion staging practices168. 
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Hence, the FIGO staging system has not changed and remains at assessing the 50% mark. I 
think the most important thing when dealing with depth invasion issues is careful 
macroscopic evaluation. Fractioning the most deeply invasive part of the cancer clearly and 
separately so it can be assessed properly and also being careful in measuring depth of 
invasion in or near fallopian tube entry in the myometrium as the fallopian corner is the 




























3 NEW DEVELOPMENTS IN EC DIAGNOSTICS 
It should be clear from the past segment that EC diagnostics is in dire need of some fresh 
and objective methods of diagnostics. There is a rapidly evolving field of genomic studies 
of EC that in the recent years has greatly expanded our knowledge of EC tumor biology as 
well as shown great promise of being directly integrated in EC diagnostics and the current 
morphologic systems of classification. 
3.1 EARLY HISTOTYPE SPECIFIC GENE MUTATION PROFILES 
As the cost of advanced sequencing has reduced and methods improved and simplified, the 
field of gene sequencing is now open for possible inclusion into everyday clinical practice. 
New challenges have however arisen as we learn more about the genetic profiles of 
different EC histotypes. ECs in general are characterized by high mutational burdens with 
somewhat overlapping gene profiles (same driver mutations seen in different histotypes) 
both within and outside of the same histotype. Tumor heterogeneity may further make 
things difficult as different areas of a tumor may show differing mutational 
profiles159,169,170. For these reasons it is difficult to purely use simple gene profile signatures 
of a tumor for diagnostics and prognostics without incorporating morphologic and IHC 
features of a tumor.  
Most endometrioid ECs display mutations on PTEN171 (a tumor suppressor gene), 
ARID1A172,173 (chromatin remodeling complex), PIK3CA174 (Oncogene) and to a lesser 
extent also KRAS175 (Oncogene) and CTNNB1176 (Beta-catenin, Cell adherence regulator 
and cell division control) mutations. About 1/5th of these tumors also display MSI, DNA 
aneuploidy and TP53 mutations (mostly in the high grade tumors)83,177.  
Serous tumors show a different profile than endometrioid tumors suggesting molecular 
screening might be of use in trying to separate these two entities diagnostically. Serous 
carcinomas instead are almost always TP53 (tumor suppressor gene) and PPP2R1A (cell 
growth and division gene) mutated. They also very frequently display copy number 
alteration and DNA aneuploidy169,172,173,178. 
Clear cell carcinomas are hard to clearly define and categorize on a molecular basis because 
they, as a group, show a very heterogenous molecular profile. A large proportion show a 
similar profile to that of endometrioid carcinomas with frequent ARID1A and PIK3CA 
mutations without any other clear-cut separating profile that distinguishes them from their 
endometrioid counterparts. However, a substantial subset of these tumors show a TP53 and 
PPP2R1A mutated profile much more akin to serous carcinomas179–181.  With the novel 
molecular categorization identified by the TCGA (see more below) it is of note that a fair 
amount of clear cell carcinomas show a POLE mutated as well as MSI mutational profile.  
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These tumors tend to biologically and clinically behave as their molecular subgroup 
irrespective of the histomorhology, meaning that POLEmut clear cell carcinomas display a 
non-aggressive clinical behavior despite being histologically classified as a high-grade 
tumors172,178. 
Un-/dedifferentiated carcinomas also display a non-specific molecular profile. They are in 
part identified with an epithelial to mesenchymal cell-transformation profile (much like 
carcinomsarcoma) showing downregulation of E-cadherin and upregulation ZEB-1 and 
HMGA (genes in part responsible for the epithelial-mesenchymal transition)182. Roughly 
70% of un-/dedifferentiated carcinomas fall into the TCGA categories of MSI and 
endometrioid-like copy-number low (see below), but are also, to a lesser extent, classified 
in the other two categories of the TCGA classification173. Outside of the TCGA 
classification these tumors are characterized by a mixed genomic profile with a mixture of 
endometrioid and serous like profile183. 
As mentioned before, carcinosarcomas are thought to be metaplastic carcinomas (epithelial 
carcinoma with metaplastic sarcomatous dedifferentiation) rather than true biphasic tumors 
based on clonal subgroup analysis on both tumor components184. Carcinosarcomas as well 
tend to have either an endometrioid type mutational profile (PTEN and ARID1A mutations) 
or a serous-like profile (TP53 and PPP2R1a mutations)172. 
To summarize the above, simple targeted sequencing is useful only when specific 
differentials and questions arise but cannot be used when broader general diagnostic and 
prognostic questions are considered. While serous and low grade endometrioid tumors have 
specific mutational profiles, the other remaining histotypes show non-specific profiles that 
fall within either of the serous or low-grade endometrioid mutational profile categories.  
 
Figure 3. Summary of mutational profiles based on histotype. Colored bars mark mutations 




3.2 TUMOR CANCER GENOME ATLAS (TCGA) GENOMIC CLASSIFICATION 
SYSTEM 
In 2013 the TCGA173 studied 370 ECs and through an integrated system using 
transcriptomic, genomic and proteomic analyses together with  MSI, somatic gene 
mutations, and copy-number alterations produced a complete genomic based classification 
system which proved to have prognostic and diagnostic value. The new system described 
four separate categories of ECs based on complete and extensive integrated genomic 
profiles instead of single gene mutation profiles described above. The four genomic 
categories of ECs produced by the TCGA consisted of:  
1. POLE-ultramutated 
This group is characterized by mutations in the POLE gene (exonuclease domain, a subunit 
of DNA polymerase epsilon), very high mutational burden, frequent mutations in PTEN, 
KRAS and PIK3CA with slightly less than a third of the cases also showing TP53 
mutations. This group is the rarest, roughly 5% of all cases, and are recognized by having 
very good outcomes with exceptionally low rates of recurrences, distant metastatic disease 
and death of disease. 
 
2. MSI/Hypermutated 
This group is characterized by frequently being of endometrioid histotype, microsatellite 
instability (MSI) status mostly due to MLH1 promoter methylation, with very high 
mutation rates, few copy-number variations and often with single gene mutations of KRAS, 
PTEN, and ARID1A. Hereditary cancers (Lynch syndrome) represent a very small 
proportion of these cases as most are sporadic and these patients had an intermediary 
outcome clinical profile.  
3. Copy-number low/MSS 
Mostly low-grade endometrioid tumors that are microsatellite stable (MSS) with low 
mutational burden and frequent CTNNB1 and PTEN mutations. Clinical outcomes were 
intermediary. 
4. Copy-number high/”Serous-like” 
About ¾ of tumors were of serous histotype and the rest high-grade endometrioid. 
Characterized by low mutational burden but by frequent copy-number alterations and 
frequent mutations in TP53 and PPP2R1A. These tumors had by far the worst outcomes.  
This original categorization of ECs based on an integrated molecular profile had significant 
impact on diagnostics, prognostics as well as direct impact on treatment possibilities. It 
impacted the field of EC research by moving the focus to a more molecular based approach, 
by itself or as an addendum to classical diagnostics. It shed light on possible targeted 
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therapies based on molecular profiles. The most important conclusions and impact the 
TCGA produced can be summarized as:  
1. Four genomic categories of ECs each with a distinct set of outcomes. The outcomes 
were irrespective of histotype and the categorization was an independent prognostic 
factor. 
2. The novel discovery of the POLEmut group has since the TCGA publication 
independantly proved to have a favourable prognosis with very few recurrances and 
death of disease185–188. This was a critical discovery as a large proportion (roughly 
30%) of these tumors have a high-grade endometrioid histology thus suggesting a vast 
number of EC patients may be overtreated. This discovery is probably the nearest one 
to make it into clinical care as it suggests that patients that have a “pure” POLEmut 
profile should receive restrctive treatment regardless of the histotype grade.    
3. The identification of highly mutated MSI group which has similar features Lynch 
syndrome carcinomas with high peritumoral infiltrating lymphocytes (TILs) and 
growth pattern heterogeneity. This identified a group of tumors with intermediate 
clincial behaviour and patients who may stand to be most beneficial from receiving 
adjuvant treatment as well as immunmodulating therapies189–191. 
4. Identification of a TP53 mutated/CN-high group with by far the worst outcomes. This 
was important in three ways. Firstly a fair number (roughly 35%) of these patients 
had endometrioid histology with a relatively high number of these actually being low-
grade identifying a group of patients where histological underdiagnosis may be 
relatively common. Secondly, despite the low-grade histology these patients had 
worse outcomes, this is clinically important as it suggests p53 status on it`s own to be 
more important indicator of possible need of adjuvant treatment rather than 
histopathological grade. Thirdly the status of p53mut identifies a patient cohort where 
aggressive treatment and extensive follow-up is warranted.  
5. ECs share some tumor biology and mutational profiles with ovarian cancers, basal 
like breast cancer and colerectal carcinoma. 
6. While many endometrioid and serous carcinomas were genomically different (mostly 
serous and low-grade endometrioid) many of them shared a genomic profile 
suggesting the possibility that theses tumors should receive the same type of treatment 






Figure 4. Summary of the TCGA findings. In figure a) a summary of findings for each 
molecular subgroup in mutations per Megabase (Mb), nucleotide substition frequency, 
and PTEN and TP53 mutational status. In b) the integrated clustering of cases and 
number of cases in each subgroup. In c) Kaplan Meier for progression free survival in 
each molecular subgroup and d) the frequencies of most common gene mutations in 
each subgroup. Reproduced from reference 173 with license from publisher. 
 
3.3 SURROGATE MARKERS OF THE TCGA CLASSIFICATION 
The described methods used by the TCGA are not feasible for use in everyday clinical 
settings. For one, using fresh frozen tissue with deep sequencing and whole exome analysis 
was and still is far too expensive and laborious to be used in pathology clinics on a daily 
basis. Because of this, a number of groups (including ourselves, see papers 3 and 4) have 
been working on implementing the TCGA findings into the clinics but in a simplified 
manner using readily available tools that wouldn’t cost an inordinate amount nor take 
excessively long time to complete, to produce so called surrogate TCGA models.  
Between the years 2016 and 2018 the Vancouver group published a series of retrospective 
studies detailing a molecular model they called ProMiseE (Proactive Molecular Risk 
Classifier for Endometrial Cancer) 192–197. In entailed trying to replicate the TCGA 
molecular classifier by targeted sequencing for POLE exonuclease domain mutations 
(POLEmut group), then using IHC markers for p53 (p53mut or p53wt) and MSI (MSH2, 
MSH6, MLH1, PMS2 to produce MMRdeficient or MSS) in order to reproduce the four 
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molecular categories found by the TCGA and see if these surrogate TCGA subgroups 
remained prognostic. This produced four categories equivalent of the TCGA; MMRd 
(MMR deficient or MSI), p53wt (equivalent to CN low of the TCGA), p53mut (CN high in 
the TCGA) and POLEmut (hypermutated/POLEmut in the TCGA). Since the categorization 
uses simple means and not a complete molecular profile a few issues will arise, firstly there 
will be cases where are all three molecular steps are neg (MMR intact, p53wt and no POLE 
mutation), these cases were categorized as p53wt (also called NSMP in other studies, no 
special molecular profile) and equivalent of the CN-low group in the TCGA. Secondly 
there will be cases that are positive for more than one molecular marker, so called 
“multiple-classifiers”. In this instance the Vancouver group performed a subgroup analysis 
of these cases and found the best way to handle them is through an algorithmic approach 
(see Figure 5 below) where they divide these multiple classifiers into one of the algorithmic 
groups. This methodology was successful in reproducing the TCGA groups and showed 
similar predictive properties and produced similar Kaplan-Meier curves as the TCGA 
classification. The surrogate molecular classifier was an independent prognostic marker of 
progression free survival (PFS) and the p53mut subgroup was an independent predictive 
marker of PFS irrespective of histology grade. 
In 2015-16 the PORTEC198–200 clinical trials and NRG/GOG201 published a series of studies 
similar to the ProMise methodology described above. The same simplified methodology for 
classifying ECs in a surrogate molecular model were used as in the ProMiseE reports, 
however with a slightly different way of designating patients into the four molecular 
classes. Multiple classifiers were deemed unclassifiable and removed from final analyses, 
and an additional layer of histopathological factors (LVSI), IHC (L1CAM expression) and 
molecular analyses (CTNNB1 exon 3 mutation) were used to group patients into four 
molecular subgroups. These studies showed similar results to ProMisE, a molecular 
classifier providing independent prognostic information making more information available 
for targeting patients in need of adjuvant treatment and in a multivariate analysis showing 
molecular subgroups (p53mut and MSI) to be statistically significant prognostic markers. 
Both ProMisE and the PORTEC classifier show similar risk discriminatory ability to the 
ESMO risk stratification system. When clinical and pathological features were integrated 
with molecular features, they resulted in improved risk stratification. 
 
The surrogate molecular methodology has multiple advantages over both conventional pure 
morphological diagnostics as well as the TCGA complete molecular classification. The 
methods used are readily available, paraffin-embedded tissue can be used for analysis, it 
can be used on biopsies alone as it is concordant with hysterectomy results195 and therefore 
yield early prognostic information, the results are reproducible and give an additional layer 
of objective findings which can be used for prognostic and therapeutic guiding purposes on 





Figure 5. Schematic overview of the methodology used to produce surrogate molecular 
marker models for both ProMisE and PORTEC. Reproduced from reference 224 with 
permission from publisher. 
  
3.4 LIMITING FACTORS OF GENOMIC-BASED CLASSIFICATION SYSTEMS 
3.4.1 General considerations 
A few important things to keep in mind that are limiting factors of genomic models. Firstly, 
most studies have been performed using a selected high risk patient group in tertiary 
referral centers with relatively high grade and stage tumors compared to the general garden 
variety population of ECs. It is therefore unclear whether or not molecular models would 
hold the same predictive power in non-selected prospective studies. Secondly, it is still 
unclear how to deal with cases where one or more markers couldn’t be evaluated (be it 
because of poor DNA quality/amount used for sequencing or if one or more IHC markers 
didn’t work). This happens fairly frequently (around 5% in most studies), perhaps these 
cases should be deemed molecularly unclassifiable. Thirdly, most studies, including the 
TCGA, have only tested tumors of endometrioid and serous histotypes, posing the question 
if same conclusions would be derived had unusual types of ECs been included. 
In a strict prognostic viewpoint both the PORTEC and ProMisE as well as the TCGA 
classification systems produce a large intermediary prognostic group consisting of MMR-
d/MSI and CN low cases. This is not optimal since the purpose of any predictive/prognostic 
model is to separate the studied groups as far as possible to create a clearly beneficial and 
clearly harmful prognostic profile. This large intermediary group could be problematic as 
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determining treatment strategies can be difficult when outcomes vary so greatly and are 
intermediate. 
3.4.2 MMRd/MSI 
MMR proteins correct base-base and deletion mispairing produced during DNA replication 
in repetitive strands of the DNA called microsatellites. Abruption of the MMR functionality 
leads to hypermutations in these scattered segments of the DNA202. There are many ways to 
determine a tumor´s MSI/MMR-d status. The most common in the clinical setting for ECs 
are MSI assays (using PCR for 5-7 known microsatellite foci and comparing tumor to 
normal tissue coupled with MLH1 methylation analysis) and IHC for MMR-poteins 
(MSH2, MSH6, PMS2, MLH1). The standardized method of testing in ECs generally 
follows the Bethesda guidelines for CRC203. MMR IHC has shown great concordance with 
more advanced techniques/assays30,204,205.  
No matter the testing procedure it is important to remember that there are different ways 
MSI occur, in the TCGA the most common pathway being epigenetic events with MLH1-
methylation173, but there are also somatic and germline (Lynch syndrome associated) 
specific mutations in each of the affected genes involved in the MMR repair mechanisms. 
The different ways MSI occur, naturally leads one to think that this should incur different 
biological, prognostic and treatment specific behaviors in different tumors depending on 
which way MSI has occurred. However, in both the TCGA and surrogate molecular models 
all the different types of MSIs are grouped together under the MMRd/MSI-group. This may 
lead to problems in the future as perhaps a subclassification of the different types of MSIs 
should improve both prognostics and tailor-making specific treatments.  
As an example of the above heterogenous MSI problematics, an NRG/GOG study206 of a 
1000 ECs grouped patients into four categories: normal/MSS, epigenetic defect, probable 
mutation or MSI-low. Epigenetic and probable mutations were associated with higher 
grade, stage and LVSI. There were no differences in OS between the groups, however, PFS 
was better for the epigenetic events group compared to the MSS group but only in a 
univariate analysis (not after adjusting for age). This study shows the many faces the 
heterogenous MSI group can have, as the hypermutated phenotype produces complex 
tumor-lymphatic system interactions and changes tumors susceptibility to chemotherapy. 
There is no question that the MSI group needs deeper analysis in order to separate both the 
aggressive behaving and treatment susceptive tumors from within this heterogenous group 
of tumors. 
3.4.3 POLEmut 
The POLE gene encodes the catalytic subunit of DNA polymerase epsilon responsible for 
DNA repair and replication. Mutations of the POLE gene can be diagnosed using Sanger 
sequencing of exons 9-14 with high accuracy. Mutations lead to a hypermutated phenotype 
and mutations are most often found in hotspots V411L, P286R and S459F188,195. One of the 
problems in this subset of ECs is answering the question of when a non-hotspot mutation 
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designates a tumor as POLEmut. In other words which uncommon mutations lead to the 
TCGA POLEmut phenotype? 
This a difficult question to answer because at this time since we don’t precisely know 
which uncommon mutations lead to a TCGA POLEmut phenotype. Because of this, the 
current consensus is a conservative approach when designating tumors to POLEmut 
surrogate molecular classifier. In other words, POLE variants should be designated as 
pathogenic only if the mutations is known to cause high mutational burden, high numbers 
of CàA single nucleotide substitutions and the mutation has previously been described in 
cancer207. Another way to approach this issue in the future may be to add analysis of tumor 
mutational burden (TMB) by NGS as a supplement to genotyping of POLE mutations208,209. 
3.4.4 Multiple-classifiers   
Roughly 3-5% of tumors are positive for more than one surrogate molecular classifier, 
termed “multiple-classifier” category. As each surrogate classifier is supposed to have it´s 
own specific prognostic, histologic and molecular profile dictating prognosis and outcome, 
the question becomes how to categorize or allocate the multiple classifier category.  
Leon-Castillo210 et al recently presented a study investigating perhaps the most interesting 
group of multiple classifiers, which includes p53mut (p53mut and POLEmut, p53mut and 
MMRd and triple positive cases with p53mut, POLEmut and MMRd) multiple classifiers. 
As p53mut tumors by far have the worst outcomes it is most important to categorize this 
group of tumors correctly. In this study they found that multiple classifiers to a large extent 
shared the same histomorhological features of “pure” POLEmut and MMRd tumors. 
Furthermore, a large subset of these multiple classifiers actually only showed a clonal 
p53mut staining pattern (meaning only a well-defined part of the tumor showed clear p53 
mutation staining and not the entire tumor) suggesting that the p53 mutational event was 
subclonal and probably only secondary to the initial driving mutation (MMRd or 
POLEmut). Further hierarchical clustering using single nucleotide variant (SNV) type and 
somatic copy number alterations (SCNAs) showed that p53mut-POLEmut tumors clustered 
with POLEmut tumors and p53mut-MMRd tumors clustered with MMRd tumors. Also, the 
clinical outcomes (PFS and OS) were very different for the multiple classiers than that of 
“pure” p53mut tumors further giving support to the idea that a p53mut is a secondary non-
driving event in these tumors. Based on these findings they suggest assigning these multiple 
classifiers to their “partner” non p53mut molecular class.  
While the above mentioned study is comprehensive, it only assigned cases of p53mut 
partnership. There still remains unanswered questions regarding non p53mut paired 
multiple classifiers (POLEmut and MMRd). In either case, the grouping of these multiple 
classifiers needs further clarification with more studies focused on the outcomes and 
features of different classes of multiple classifiers.  
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3.5 ADDITIONAL FACTORS / SUBCLASSIFICATION BEYOND THE TCGA  
The discussion above on the limitations of a molecular classification should be concluded 
with this; at the time being molecular categorization is not final nor complete. There is still 
a lot of work to do in order to deal with the biological and prognostic heterogeneity that 
exists within in each class.  
Perhaps the most symbolic for this is the surrogate molecular class of p53wt/NSMP. This 
group of tumors is negative for all surrogate molecular markers and deemed equivalent to 
the CN low TCGA category. Recent studies have revealed ways to further subclassify these 
tumors and perhaps further branch the molecular classifier. These tumors often (30-50%) 
show CTNNB1 mutations which in several studies have shown worse outcomes211,212 
within this molecular group suggesting the possible need of at fifth molecular group termed 
“NSMP-CTNNB1”.  
L1 cell adhesion molecule (L1CAM) is a molecule member of the immunoglobulin 
superfamily. It has previously been shown to be an early part carcinogenesis of many 
cancer types213. Expression of L1CAM in ECs is associated with advanced stage, lymph 
node metastasis and high grade. In low stage cancers expression is associated with lower 
OS and PFS192,193,214–216. Adding L1CAM staining onto the molecular classifier would yield 
further improved subdivision of the NSMP molecular group. 
LVSI is defined as unequivocal tumor cells found in an endothelial lined vascular space 
found outside the invasive front of the tumor. We have long known that presence of LVSI 
is a negative indicator, increasing risk of local recurrences and local as well as distant 
metastasis217,218. Fairly recently, substantial or extensive LVSI (defined as multifocal LVSI 
around the tumor, usually of more than 5 blood vessels) has been shown to be more 
predictive of worse outcomes219, this applies to all the molecular subgroups of tumor. These 
results suggest that substantial LVSI should lead to more extensive adjuvant treatment. 
Finally, within the NSMP group SCNAs in chromosome 1q32.1 correlated with worse 
PFS220. Interestingly, the old workhorses ER/PR IHC expression, used in EC diagnostics 
and prognostics for a long time97,221, don’t seem to add additional prognostic benefit in 










4 NEW DEVELOPMENTS IN EC CLINICAL CARE AND 
RESEARCH 
4.1 IMPLEMENTING A GENOMICS BASED CLASSIFICATION SYSTEM IN 
PATIENT CARE 
Between the years 2016-2020 a series of reviews222–227 of the genetics of ECs detailed a few 
approaches that can be taken to incorporate the findings of the TCGA and the TCGA 
surrogate molecular markers into clinical practice. This new understanding of genomic 
classification of ECs have led to a better understanding of the tumor biology and added an 
objective layer of risk stratification and improved prognostication.  The hope is that adding 
this information to current clinicopathologic risk stratification will aid in further stratifying 
patient groups and tailor-making specific treatment. However, this remains to be proven in 
future prospective trials. The group of EC patients that may benefit the most from this 
integrated diagnostic methodology are patients in the intermediary risk groups, since this is 
where most unanswered questions lie regarding extent and selection of treatment. 
4.1.1 Implementing POLEmut profile in patient care 
A large number of studies have now shown the excellent outcomes of the POLEmut group 
in regards to OS and PFR187,228–231. As a substantial portion of these tumors are either high 
grade, high stage or both (and therefore in most of these studies received adjuvant 
treatment) one must be cautious in interpreting these excellent outcomes and wonder if 
POLEmut tumors have good outcomes because they are ultramutated, immunogenic and 
thus highly susceptible to treatment rather than some inherent beneficial tumor biology. 
There is, however, considerable data to support an innate benevolent behavior hypothesis. 
In the PORTEC-1 study POLEmut patients had 100% PFS in a 10 year follow up124,200 
without any adjuvant treatment. POLEmut embryonic stem cells did not prove to be more 
chemo- or radiation sensitive in patients from the same study232. The results of the 
PORTEC-3 trial with high-risk ECs show excellent outcomes in both treatment arms of 
POLEmut tumors (RT and CTRT). All of the above support the notion of an innate indolent 
behavior of POLEmut tumors. Perhaps because they are hypermutated and immunogenic 
the immune system can defeat the tumor on its own. Therefore, the evidence seems 
sufficient to start clinical prospective trials including POLE mutation analysis and limiting 
the adjuvant treatment (and perhaps the extent of primary surgery) in patients 
demonstrating a pathogenic POLE mutation irrespective of histology grade and surgical 
stage (up to high-risk patients) so as to avoid unnecessary side effects and overtreatment of 
these patients.  
4.1.2 Implementing p53mut profile into patient care 
Much like POLEmut there is now substantial data supporting the poor outcomes of the 
p53mut group of tumors irrespective of histotype/grade and stage230,233,234. This suggests 
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that in the preoperative setting a p53mut profile on biopsy should warrant an extensive 
surgical staging including LA, peritoneal lavage as well as possible omental resection. 
There is however an argument to be made that these patients will in most cases be high 
stage after surgery and thus more focus should be on postoperative adjuvant treatment 
instead of extensive primary surgery. Prospective clinical trials will have to examine this 
question further in the future. 
The current evidence of poor outcomes is sufficient to support the notion that these patients 
should receive an intensified adjuvant treatment course. For patients with an intermediate-
high risk profile intensifying treatment from VBT to EBRT235. High-risk patients with a 
p53mut tumor benefit from further adding chemotherapy to RT with improved PFS as a 
result230.  
4.1.3 Implementing MMRd profile into patient care 
There is now a general agreement that MMR testing should be performed for all patients 
with EC, not least in order to discover possible Lynch syndrome236. MMRd tumors are 
similar to POLEmut tumors, frequently showing endometrioid histology with TILs and 
high mutational burdens. They, however, differ in prognostic significance though as MMRd 
tumors are intermediary in outcomes. Because they are intermediary it is difficult to 
determine appropriate extent of adjuvant treatment. There is scarce evidence on how to 
adjust treatment recommendation for this patient group.  
The results from the PORTEC-2 and 3 studies found that VBT is equally as effective as 
EBRT in decreasing risk of lymph node recurrences in high-intermediate risk patients 
without any adverse factors (L1CAM presence, substantial LVSI and/or p53mut) in this 
patient group. Additionally, for high-risk patients the addition of chemotherapy to EBRT 
did not add any prognostic benefit230,237. These results suggest possible benefits of 
reduction in treatment for high-risk patients. 
4.2 ROLE OF MOLECULAR PROFILES IN ADVANCED OR RECURRENT 
DISEASE 
There are few treatment possibilities for patients with advanced EC. No clinical trials 
exploring possible treatment options in advanced (distant, FIGO stage 3 and above) EC 
cases in the context of molecular profiles exist. There are theoretical ideas that immune-
checkpoint inhibitors (such as PD-1 blockade) may be of benefit for patients with MMRd 
and/or POLEmut tumors because these tumors carry a high mutational burden, are 
immunogenic and histologically often seen with numerous TILs238–240. POLEmut tumors, 
however, show a trend towards good outcomes (not enough few cases so far with advanced 
disease to make a clear-cut conclusion) with current standard treatment regimens possibly 
indicating no need for immunotherapies for these patients. However, MMRd tumors with 




The most vital question though remains in patients with p53mut tumors and advanced 
disease, in part because they have the worst outcomes but also because these tumors tend to 
present with an advanced disease. There is no current logical reason for these to be 
candidates for immunotherapy, however targeted therapies may be a solution. Several 
recent studies have shown serous carcinomas (often p53mut) to overexpress Her2 (ERBB2) 
in between 20-70% of cases241–243. A recent phase II trial showed benefits when adding 
trastuzumab (monoclonal antibody against the Her2 receptor) to chemotherapy in the form 
of increased PFS244. This may be a potential target for future prospective studies in regards 
to p53mut tumors.  
Another possible option is Poly ADP-ribose polymerase inhibitors (PARPi). These agents 
work by blocking single-strand repair mechanisms leading to conversion to double-strand 
breaks which are mainly repaired by homologous recombination (HR) mechanisms, in HR-
deficient cells this leads to accumulation of double-strand breaks and causes apoptosis245. 
There are recent studies showing high grade ECs, including p53mut ones, have a sizeable 
proportion of tumors which are HR-deficient246,247. There are current ongoing clinical trials 
investigating the potential effect on PARPi in the setting of advanced ECs.   
4.3 PROSPECTIVE CLINICAL TRIALS 
The PORTEC-4a237,248 clinical study is the first prospective study fully incorporating 
molecular classifiers as one of the main deciding factors for choice of intervention. It 
includes high-intermediate risk ECs in order to study effect of selecting patients for suitable 
adjuvant treatment using a molecular based risk profile. It involves two study arms, the 
control arm with standard VBT and in the study arm patients selected based on their 
molecular profile to either observation, VBT or EBRT. The study is ongoing and aims to 
measure effects on local vaginal recurrence as well as overall PFS and OS.  
4.4 SENTINEL NODE BIOPSY 
As described earlier LA, has been a standard part of surgical staging of ECs for 30 years 
since it was shown that roughly 20% of early stage patients had metastatic disease102. The 
risk of metastatic disease, however, is lower in low-grade ECs249,250 and there is no proven 
effect on OS when LA114 is performed, only improved surgical staging. This has led to the 
belief that LA in patients with low-grade ECs may be overtreated and exposing patients to 
unnecessary surgical risk with increased morbidity251,252.  
Because of the above facts, a large number of studies have investigated various techniques 
with differing injection sites and tracers in order to establish a routine sentinel node 
protocol for EC patients with the hopes of finding a suitable staging method so as to not 
overtreat while at the same time maintaining high degree of surgical staging accuracy. The 
current preferred method is injection at four points in the cervix with indocyanine green 
with near infrared fluorescent imaging detecting roughly 85% sentinel lymph nodes, thus 
making a complete LA redundant in most low-grade ECs, and has since become an NCCN 
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guideline253–255. The positive rate of sentinel lymph nodes using this method is about 10-
15%254. 
While there is no standardized way to process sentinel lymph nodes from a surgical 
pathology point of view, numerous studies have shown a simple “ultrastaging” protocol (1 
level of hematoxylin and eosin followed by 2 unstained levels at 250 micrometers followed 
by IHC keratin cocktail) proved to be sufficient with no added benefit of more extensive 
staging protocols256,257. 
























5 SUMMARY OF RESEARCH AND PUBLICATIONS 
5.1 AIMS 
General aims of the thesis were to examine different ways to improve EC diagnostics. To 
achieve this, we used a three-tiered approach using morphological, IHC and biomarkers and 
finally molecular/genetic markers as described below. 
Specifically: 
In study 1 the aim was to evaluate a cell type independent binary morphological system`s 
performance in the endometrial biopsy setting and to assess a binary grading system`s 
weaknesses and strengths in comparison to the traditional FIGO grading system. 
In study 2 the aim was firstly to evaluate the interobserver agreement between 12 
consultant gynecologic pathologists in biopsy diagnosis of EC. Secondly to evaluate if a 
biomarker panel (p53, ER, PR, and DNA ploidy analysis) supplementing morphology 
would improve the interobserver reproducibility. Third, to test whether ‘‘reflex’’ or 
‘‘reflective’’ testing is optimal. Lastly evaluate the role of each biomarker in a statistical 
model to determine which biomarkers are contributing to upgrading and downgrading.		
In study 3 the aim was to investigate if a simplified clinically applicable surrogate TCGA 
molecular model could predict outcome of a “general population” of ECs and to compare it 
to current risk stratification models as well as FIGO grade and stage.  
In study 4 we wanted to analyze the clinical and genotypic characteristics of POLEmut 
tumors. The aim was to evaluate which POLE mutations could be associated with the 






5.2 MATERIALS AND METHODS 
In study 1 the cohort consisted of 70 women who had a diagnosis of EC (endometrioid, 
clear cell, mixed or serous) and who had both biopsy and hysterectomy specimens available 
at Karolinska University Hospital in Solna. The hysterectomy specimen was rereviewed to 
establish an endpoint diagnosis. The pre-surgery biopsies were independently reviewed by 
three reviewers using the standard FIGO grading system and then rereviewed a week later 
using a cell type independent (CTI) binary grading system. After review, all biopsies were 
assigned a consensus diagnosis should discrepancy occur. Reviews were done blindly and 
cases were shuffled between reviews. The CTI system uses a point scale assessing growth 
pattern, nuclear atypia and mitotic index instead of histotype assessment.  
Agreement was assessed using percentages and kappa where the strength of agreement by k 
values were interpreted as follows: 0.00 to 0.20, poor; 0.21 to 0.40, fair; 0.41 to 0.60, 
moderate; 0.61 to 0.80, substantial; 0.81 to 1.00, almost perfect.  
In study 2 12 gynecological pathologists reviewed 70 endometrial biopsy slides, first 
without any aid from biomarker panel and then after aid of biomarker panel after which 
results of their diagnoses were compared. One part of the study was to evaluate reflex or 
reflexive testing (all or only some cases deemed difficult), this was done by allowing a 
change of diagnosis on all cases (reflex testing) or only after the pathologist “ordered” the 
biomarker panel (reflective testing).  
The tumor grade were binarized (high grade and low grade) for statistical analysis. Up- and 
downgrading was defined as a diagnosis change from low- to high grade or vice versa. The 
pairwise interobserver agreement between each of the 12 reviewers was calculated using 
the frequency of percent agreement and Cohen kappa value. The strength of agreement was 
assessed the same way as described above in study 1. Simple and multiple generalized 
linear mixed models with the logit link function where used, raters were considered as a 
randomized variable and other variables were fixed to assess each biomarkers effect on up- 
or downgrading. For descriptive statistics, we used the odds ratio. A P-value of <0.05 was 
considered statistically significant.		
In study 3 a collaborative effort between Karolinska University Hospital and Bern 
University Hospital defined a cohort (KimBer cohort) of 604 women with unselected 
general population ECs on which a surrogate molecular marker was applied. The molecular 
markers applied tried to replicate the TCGA defined molecular categories. In doing so, IHC 
on tissue microarrays (TMA) consisting of MSH2, MSH6, PMS2, MLH1 (defining an 
MMRd group) and p53 (defining a p53mut group) was performed and Sanger sequencing 
of exons 9-14 of the POLE gene (defining a POLEmut group) was conducted. Cases 
negative for all the markers above were called neg molecular markers (also NSMP in other 
studies, no special molecular profile) and ECs positive for more than one marker were 
grouped in a multiple classifier positive group.  
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Associations between predictive models and clinical factors were analyzed using non-
parametric tests. Kruskal-Wallis test was used for continuous variables and Fisher-exact, 
log-rank and Chi-square for continuous variables. In analyzing the surrogate molecular 
markers predictive performance of OS, Disease specific survival (DSS) and PFS we used 
univariable and multivariable (adjusted) analysis with both Kaplan-Meier curves and Cox-
proportional regression. To compare the performance of today’s standard risk assessments 
versus the surrogate molecular model we calculated Harrell`s C-index for each model`s 
discriminatory ability. 
In study 4 we sequenced 604 ECs with Sanger sequencing of POLE gene exons 9-14. 
When sequencing proved a mutation previously not described as a hotspot mutation, a 
DNA sample of normal non-tumor myometrium was sequenced to rule out germline 
mutation. After this the different discovered POLE mutations were classified as known 
hotspot POLE mutations (P286R, V411L, S297F, A456P and S459F), POLE mutations 
with a previously described high tumor mutational burden which is consistent with a 
POLEmut phenotype, and POLE mutations of unknown significance.  
Fisher`s exact test and independent T-test were used to compare the POLEmut and non 
POLEmut groups. Survival analysis was calculated using Kaplan-Meier curves and with 
log rank test. For assessing risk factors for PFS and DSS, Cox regression analysis of all the 

















In study 1 the results show that the CTI and FIGO grading systems were comparable in 
accuracy of diagnosis (85.7 and 84.3% with kappa values of 0.71 and 0.69 for FIGO and 
CTI respectively) with similar sensitivity and specificity in discerning between low- and 
high-grade diagnosis. The interobserver agreement in the biopsy setting was similar 
between the two classification systems as well. The same misdiagnosis tendencies appeared 
to be true for both grading systems, in that overgrading low-grade tumors happened in 
about 1/5th of the cases. The assessment of nuclear atypia was the least reproducible marker 
in both systems. 
In study 2 we found that the interobserver agreement between the 12 pathologists increased 
from 75,8%, kappa = 0.52 to 84%, kappa= 0.68 after the use of the biomarker panel. 
Diagnostic agreement to final hysterectomy diagnosis also increased with use of the panel, 
going from 83.6% to 88.7% agreement after incorporating the panel in biopsy diagnosis 
(p<0.05). There was no difference in interobserver agreement when using reflective or 
reflex testing. The two biomarkers p53 IHC and DNA ploidy analysis were the only two 
markers showing significant effect on up-or downgrading of tumors.    
In study 3 we found that a surrogate molecular model performed well in replicating the 
TCGA molecular classifier and produced similar survival curves. However, the molecular 
markers predictive ability was not significantly better than current ESMO risk stratification 
nor could we find any added prognostic benefit when supplementing ESMO with the 
molecular markers.  
In study 4 we found 38/599 (6.3%) patients with POLE hotspot mutations. An additional 3 
tumors had POLE mutations previously described as having high mutational burden, and 
another 15 tumors had POLE mutations of unclear significance. The POLEmut phenotype 
patients were significantly associated with lower age, nulliparity and smoking. No 
significant histopathological morphologic phenotype was found but most tumors were 
endometrioid and of low ESMO risk group. When comparing outcomes, only one patient 
with the POLEmut phenotype had a recurrence (1/38, 2,7%) compared to 16.9% (89/526) 
in the non POLEmut group. A significant difference in regards to PFS (p=0.023) was found 
between the groups but no differences in regards to OS was found since the one patient 
with recurrence died of disease. A Cox regression analysis however, did not show any 
statistically significant difference between the POLEmut and non-POLEmut groups 









5.4 DISCUSSION, CONCLUSIONS AND FUTURE PROSPECTS 
From the mid-80s to the early 2010s the research area of EC and EC diagnostics has been 
fairly dormant without any major significant changes to diagnostics. But the 2013 TCGA 
article characterizing the molecular profiles of ECs kicked the research area into a frenzy. 
This is clearly reflected in the timeline of my thesis; at the beginning in the years 2014-
2015 much focus lay on morphologic criteria and how to refine and clearly categorize each 
component of morphologic diagnostics to somehow reach a clear histologic grade with high 
interpersonal concordance. This was also our main initial focus, namely new ways of 
histologically define EC diagnostics. In an attempt to study these changes, we conducted 
study nr 1 in which the main conclusion is that the CTI system does not appear to add any 
significant benefit over standard FIGO grading in the biopsy setting. Using nuclear grade 
(used in both systems) causes the same lack of reproducibility. For the CTI systems, 
especially in the biopsy setting, the main problems were because of small amount of tumor 
material making it difficult to assess mitotic index and overall growth architecture as solid 
squamous areas were difficult to assess together with small amount of tumor material. In 
the biopsy setting, where lack of tumor representability is a common problem, it does not 
appear that CTI adds any great benefit compared to existing grading system. 
These are, unfortunately, the same conclusions many other studies examining different 
ways to improve EC diagnostic histopathology came to. It seems the road of strictly 
morphologic diagnostics of EC has come to an end, and fresh air in the form of biomarkers 
and molecular pathology was needed to breathe new life into the field and lead to 
improvements. Thus, in study 2 we showed significant benefit of adding a simple 
biomarker panel in improving interobserver reproducibility. Selective use of the panel is 
sufficient on morphologically difficult cases as testing on all cases was not found to 
significantly improve interobserver agreement. The study shows great diagnostic benefits 
when using a simple biomarker panel, and the use was most beneficial when assessing high 
grade and mixed carcinomas which are diagnostically challenging.  
From morphologic and IHC studies focus shifted to molecular/genomic parameters since 
many research groups in the area had showed great success in replicating the TCGA 
findings using simpler methods. We demonstrated the same, shown in study 3 we could 
replicate the TCGA findings using a simple surrogate molecular. We could, however, 
unlike many other research groups, not find any added prognostic benefit of a surrogate 
molecular marker, neither on its own nor when added as supplemental information on top 
of today`s risk stratification models. We conclude from this that a surrogate molecular 
marker isn’t a better predictive factor in a study consisting of a general non-selected EC 
cohort. In other words, the less high-grade and high-stage tumor in a cohort the less power 
a molecular model has. It may mean we were simply underpowered as recurrences and OS 
events were quite rare in comparison to other studies reporting different results. 
Nonetheless, there are clear benefits with the addition of genomic data that are not strictly 
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and only prognostic, as these can aid in patient selection for adjuvant treatment and perhaps 
even propose patients compatible with targeted therapies and immunotherapies in advanced 
and/or recurrent disease.  
As the molecular/genomic field has evolved and matured between the years 2015-2020, the 
focus has slightly shifted to subcategorization within each group of molecular classifiers 
and on integrating genomic data with histopathologic parameters. As such, we conducted 
study nr 4 detailing the phenotype of POLEmut tumors. As one of the only studies 
conducting a full sequencing of exons 9-14 of the POLE gene we found mostly previously 
described hotspot mutations but also found substantial mutations with unknown 
significance. Correctly categorizing POLEmut patients as such is important because it 
signifies exceedingly good outcomes and suggests these patients could benefit from 
restrictive treatment. This study shows that, when clearly defined as either hotspot 
mutations and/or POLE mutations with a known hypermutated phenotype, this patient 
group of POLEmut had very good outcomes with only 1 recurrence in 38 patients. The Cox 
regression couldn’t show any significant difference between POLEmut and non POLEmut 
tumors, however we believe again this was because we are dealing with a low risk EC 
population where both events and POLE mutations are rare, and thus we believe we were 
underpowered.  
In general, the field of EC research has matured and is fast moving towards genomic 
supplementation aiding and supplementing diagnosis, as well as risk stratification and 
guiding treatment decisions. I believe molecular and histopathological diagnosis has 
already answered a great deal for a strata of EC patients; namely the low- grade and stage 
group with no adverse risk factors (such as a p53mut molecular phenotype), it seems that 
current treatment is plenty sufficient for these patients as they extremely rarely recur and 
die of disease. 
Future research, I believe, will be focused on answering the following two questions; is 
there a better way to further stratify molecular groups and is there room for further 
stratification within each molecular group? Case in point, which MMRd tumors behave 
aggressively and which are mainly indolent? More importantly, do any of them, in 
advanced and/or recurrent disease, respond to immunotherapy and if so which ones. Other 
examples in the theme of further subdivision and more subclassification; are there more 
markers that have yet to be evaluated in order to achieve a better subdivision in the NSMP 
molecular group so we better can predict NSMP behavior. Will the highly aggressively 
behaving p53mut group branch onto its own, independent of histology, and be subject to 
targeted treatments early on in treatment decisions irrespective even of stage? 
The other main question that hopefully soon will be answered is whether molecular groups 
onto themselves can guide early adjuvant treatment decisions. While molecular/genomic 
incorporation is still young in the EC field there is already sufficient evidence that this may 
be the case and clinical trials are already ongoing trying to answer these questions. I think 
one of the most exciting findings is the POLEmut group. While early clinical trials will 
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definitively answer the question of whether these patients need any adjuvant treatment at 
all, the superb outcomes of these patients suggest a possibility of even more moderate 
treatment possibilities, perhaps even omission of surgery and a simple wait and watch 
program may be in the works for the future. The other focus will lie on the other end of the 
spectrum, patients with high- grade and stage tumors with adverse molecular features. 
Which of these patients are susceptive for targeted therapies (and if they are susceptible, 
which targeted therapies) will be a major focus in the future as outcomes for these patients 
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